A phase 1/2 trial of MRG006A in advanced solid tumours, run by Lepu Biopharma Co., Ltd., now recruiting.
A Study of MRG006A in the Treatment of Patients With Advanced Solid Tumors is a phase 1/2 interventional study registered as NCT07093970 by Lepu Biopharma Co., Ltd., with 343 participants planned, started 2024-07-24 and due to reach its primary completion in 2027-12. Interventions recorded: MRG006A.
Shares Lepu Biopharma, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.